» Articles » PMID: 18829672

Clinical Course and Lung Function Change of Idiopathic Nonspecific Interstitial Pneumonia

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2008 Oct 3
PMID 18829672
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Most studies of idiopathic nonspecific interstitial pneumonia (NSIP) have primarily studied mortality. In order to clarify the detailed outcome and prognostic markers in idiopathic NSIP, the clinical course with initial radiological and clinical features was analysed. The clinical course of 83 patients who were classified with idiopathic NSIP (72 fibrotic, 11 cellular; 27 males and 56 females; mean+/-sd age 54.4+/-10.1 yrs) was retrospectively analysed. In fibrotic NSIP, 16 (22%) patients died of NSIP-related causes with a median (range) follow-up of 53 (0.3-181) months. Despite the favourable survival (5-yr 74%), patients with fibrotic NSIP were frequently hospitalised with recurrence rate of 36%. Reduced forced vital capacity at 12 months was a predictor of mortality. On follow-up, lung function was improved or stable in approximately 80% of the patients. The extent of consolidation and ground-glass opacity on initial high-resolution computed tomography correlated significantly with serial changes of lung function, and the presence of honeycombing was a predictor of poor prognosis. During follow-up, eight (10%) patients developed collagen vascular disease. In conclusion, the overall prognosis of fibrotic nonspecific interstitial pneumonia was good; however, there were significant recurrences despite initial improvement and a subset of the patients did not respond to therapy. Some patients developed collagen vascular diseases at a later date.

Citing Articles

Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases.

Vastag Z, Tudorache E, Traila D, Fira-Mladinescu O, Marc M, Oancea C Biomedicines. 2024; 12(11).

PMID: 39595138 PMC: 11591599. DOI: 10.3390/biomedicines12112572.


CT-based body composition analysis and pulmonary fat attenuation volume as biomarkers to predict overall survival in patients with non-specific interstitial pneumonia.

Salhofer L, Bonella F, Meetschen M, Umutlu L, Forsting M, Schaarschmidt B Eur Radiol Exp. 2024; 8(1):114.

PMID: 39400764 PMC: 11473462. DOI: 10.1186/s41747-024-00519-0.


Imaging in the diagnosis and management of fibrosing interstitial lung diseases.

Lederer C, Storman M, Tarnoki A, Tarnoki D, Margaritopoulos G, Prosch H Breathe (Sheff). 2024; 20(1):240006.

PMID: 38746908 PMC: 11091715. DOI: 10.1183/20734735.0006-2024.


Successful Immunosuppressive Therapy for Interstitial Lung Disease Associated with Sjögren's Syndrome with Double-positive Anti-SS-A and Anti-centromere Antibodies.

Suzuki K, Akiyama M, Kondo Y, Saito S, Kikuchi J, Hanaoka H Intern Med. 2024; 63(21):2987-2990.

PMID: 38432977 PMC: 11604387. DOI: 10.2169/internalmedicine.3384-23.


Walking the path of treatable traits in interstitial lung diseases.

Amati F, Spagnolo P, Ryerson C, Oldham J, Gramegna A, Stainer A Respir Res. 2023; 24(1):251.

PMID: 37872563 PMC: 10594881. DOI: 10.1186/s12931-023-02554-8.